MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206424 | Name: Telatinib
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Telatinib, also known as BAY 57-9352, is a potent and orally active VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Telatinib treatment was well tolerated. The observed single agent antitumor activity in heavily pretreated CRC patients was limited. Pharmacodynamic results are suggestive for the biological activity of telatinib justifying a further evaluation of telatinib bid in combination with standard chemotherapy regimens in CRC patients.

Chemical Structure

Telatinib
Telatinib
CAS#332012-40-5 (free base)

Theoretical Analysis

MedKoo Cat#: 206424

Name: Telatinib

CAS#: 332012-40-5 (free base)

Chemical Formula: C20H16ClN5O3

Exact Mass: 409.0942

Molecular Weight: 409.83

Elemental Analysis: C, 58.61; H, 3.94; Cl, 8.65; N, 17.09; O, 11.71

Price and Availability

Size Price Availability Quantity
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
500mg USD 1,250.00 Ready to ship
1g USD 1,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
332013-26-0 (mesylate) 332012-40-5 (free base)
Synonym
BAY 57-9352; BAY 57-9352; BAY57-9352; Telatinib.
IUPAC/Chemical Name
4-(((4-((4-chlorophenyl)amino)furo[2,3-d]pyridazin-7-yl)oxy)methyl)-N-methylpicolinamide
InChi Key
QFCXANHHBCGMAS-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
SMILES Code
O=C(C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1)NC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Biological target:
Telatinib (Bay 57-9352) is an inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.
In vitro activity:
Telatinib increased the accumulation of MX and decreased the efflux rate in cells transfected with ABCG2. Furthermore, telatinib did not affect either expression or localization of ABCG2. However, effect of telatinib on localization still needs to be confirmed by more sensitive means. It indicates that increase in MX levels in the cells expressing ABCG2 is because of inhibition of ABCG2 drug efflux function by telatinib. Telatinib stimulated the ABCG2 ATPase activity in a concentration dependent manner. In addition telatinib effectively reduced the ATP-dependent uptake of [3H]-E217βG in membrane vesicles obtained from ABCG2-482-R2 without affecting the uptake in the parental HEK293/pcDNA3.1 vesicles. This shows the ability of telatinib to directly interact with the ABCG2 membrane transporter and thereafter inhibiting its transport activity at sub-micromolar concentrations. Reference: Biochem Pharmacol. 2014 May 1; 89(1): 52–61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983711/
In vivo activity:
The H460/MX20 tumor growth rate recorded over a period of 18 days was significantly slow in the telatinib-DOX combination group compared to vehicle, telatinib alone or DOX alone groups (Fig. 6B). In addition, telatinib in combination with DOX also produced a significant reduction in tumor size and weight (Fig. 6D and ​7B). It should be noted that telatinib by itself also significantly decreased the growth rate of H460 and H460/MX20 xenografts. However, there was no significant difference between the effects of telatinib alone or combination on the H460 xenografts (Fig. 6A, 6C and ​and7A).7A). DOX with or without telatinib did not produce any apparent toxicity or weight loss (Fig. 7C). Immunohistochemical analysis of the excised tumors showed expression of ABCG2 in H460/MX20 tumors and there was no significant difference in the expression level of the ABCG2 among different groups. Taken together, telatinib did not increase the toxicity; instead it improved the efficacy of DOX in the H460/MX20 xenograft model. Reference: Biochem Pharmacol. 2014 May 1; 89(1): 52–61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983711/
Solvent mg/mL mM
Solubility
DMSO 44.3 108.17
DMSO:PBS (pH 7.2) (1:2) 0.3 0.81
DMF 5.0 12.20
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 409.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012. Epub 2014 Feb 22. PMID: 24565910; PMCID: PMC3983711.
In vitro protocol:
1. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012. Epub 2014 Feb 22. PMID: 24565910; PMCID: PMC3983711.
In vivo protocol:
1. Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012. Epub 2014 Feb 22. PMID: 24565910; PMCID: PMC3983711.
1: Song Q, Wang P, Wu J, Lu M, Xia Q, Shi Y, Wang Z, Ma X, Zhao Q. Analysis of the role of CHPF in colorectal cancer tumorigenesis and immunotherapy based on bioinformatics and experiments. Discov Oncol. 2024 Sep 18;15(1):458. doi: 10.1007/s12672-024-01340-2. PMID: 39292317; PMCID: PMC11410747. 2: Ong SLM, Baelde HJ, van IJzendoorn DGP, Bovée JVMG, Szuhai K. Identification of stable housekeeping genes for induced pluripotent stem cells and -derived endothelial cells for drug testing. Sci Rep. 2022 Sep 28;12(1):16160. doi: 10.1038/s41598-022-20435-w. PMID: 36171445; PMCID: PMC9519970. 3: van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG. Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6. PMID: 29511030. 4: Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, Cheng R, Kim J, Orlando M, Kang YK. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Res Treat. 2017 Oct;49(4):851-868. doi: 10.4143/crt.2016.176. Epub 2017 Jan 3. PMID: 28052652; PMCID: PMC5654167. 5: Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel). 2014 Sep 29;6(4):1925-52. doi: 10.3390/cancers6041925. PMID: 25268163; PMCID: PMC4276951. 6: Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 2014 May 1;89(1):52-61. doi: 10.1016/j.bcp.2014.02.012. Epub 2014 Feb 22. PMID: 24565910; PMCID: PMC3983711. 7: Benjamin B, Sahu M, Bhatnagar U, Abhyankar D, Srinivas NR. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds? Arzneimittelforschung. 2012 Apr;62(4):194-201. doi: 10.1055/s-0031-1299772. Epub 2012 Jan 30. PMID: 22290114. 8: Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, Fasol U, Büchert M, Krätzschmer J, Delesen H, Rajagopalan P, Christensen O. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Vasc Cell. 2011 Jul 29;3:16. doi: 10.1186/2045-824X-3-16. PMID: 21801343; PMCID: PMC3170612. 9: Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui- Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol. 2011 Nov;22(11):2508-2515. doi: 10.1093/annonc/mdq767. Epub 2011 Mar 4. PMID: 21378200. 10: Xie Q, Wondergem R, Shen Y, Cavey G, Ke J, Thompson R, Bradley R, Daugherty- Holtrop J, Xu Y, Chen E, Omar H, Rosen N, Wenkert D, Xu HE, Vande Woude GF. Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4105-10. doi: 10.1073/pnas.1015181108. Epub 2011 Feb 22. Erratum in: Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5472. Daughtery-Holtrop, Jennifer [corrected to Daugherty-Holtrop, Jennifer]. PMID: 21368131; PMCID: PMC3053964. 11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):517-48. doi: 10.1358/mf.2010.32.7.1549223. PMID: 21069103. 12: Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. PMID: 20233884. 13: Steeghs N, Gelderblom H, Wessels J, Eskens FA, de Bont N, Nortier JW, Guchelaar HJ. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs. 2011 Feb;29(1):137-43. doi: 10.1007/s10637-009-9347-0. Epub 2009 Nov 19. PMID: 19924384; PMCID: PMC3016151. 14: Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. PMID: 19636022. 15: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949. 16: Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K. Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer. 2008 Nov 18;99(10):1579-85. doi: 10.1038/sj.bjc.6604724. PMID: 19002179; PMCID: PMC2584942. 17: Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, Putter H, Rabelink TJ, de Koning E. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008 Jun 1;14(11):3470-6. doi: 10.1158/1078-0432.CCR-07-5050. PMID: 18519779. 18: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PMID: 17805439. 19: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71. PMID: 17344945.